SIRS THERAPEUTICS
SIRS THERAPEUTICS
Industry:
Health Care Therapeutics
Address:
Munich, Bayern, Germany
Country:
Germany
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
0
Similar Organizations
Akashi Therapeutics
Akashi Therapeutics is a clinical stage biopharmaceutical company.
Syndya Therapeutics
Syndya Therapeutics is a 3D combinatorial, phenotypic screening company.
ZWI Therapeutics, Inc.
ZWI Therapeutics is a biotech company developing a new polymer to reduce immunogenicity and aid pharmacokinetics of protein therapeutics.
Investors List
Wellington Partners
Wellington Partners investment in Seed Round - SIRS Therapeutics
More informations about "SIRS Therapeutics"
SIRS Therapeutics
SIRS Therapeutics GmbH Türkenstraße 5 80333 München Handelsregister: München 240453 VAT-ID: DE331612834 Kontakt: [email protected]See details»
SIRS Therapeutics - Crunchbase Company Profile & Funding
Where is SIRS Therapeutics 's headquarters? SIRS Therapeutics is located in Munich, Bayern, Germany. Who invested in SIRS Therapeutics? SIRS Therapeutics is funded by Wellington …See details»
SIRS Therapeutics - PitchBook
SIRS Therapeutics General Information Description. Producer of pharmaceutical drugs intended to treat acute respiratory distress syndrome. The company's drug is a fibrin-derived peptide to …See details»
SIRS Therapeutics GmbH - Drug pipelines, Patents, Clinical trials
Explore SIRS Therapeutics GmbH with its drug pipeline, therapeutic area, technology platform, 1 news.See details»
SIRS Therapeutics - Funding, Financials, Valuation & Investors
Apr 15, 2020 Organization. SIRS Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Funding Rounds 1. Lead …See details»
SIRS Therapeutics - Company Profile - Tracxn
SIRS Therapeutics - Developer of therapeutics for vascular disorder. Raised funding over 1 round from 1 investor. SIRS Therapeutics has 11 competitors.See details»
SIRS Therapeutics GmbH Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for SIRS Therapeutics GmbH of München, Bayern. Get the latest business insights from Dun & Bradstreet.See details»
Wellington invests in SIRS Therapeutics to develop FX06 for …
Apr 15, 2020 Wellington Partners today announced a seed investment into newly founded SIRS Therapeutics, Munich, Germany. With the investment, SIRS has secured the joint ownership …See details»
Wellington Ventures makes seed investment in SIRS Therapeutics
Apr 16, 2020 With the investment from Wellington, SIRS and Austria-based F4 Pharma GmbH will jointly own all rights on FX06, which is a fibrin-derived peptide to treat patients with acute …See details»
SIRS Therapeutics - Products, Competitors, Financials, Employees ...
SIRS Therapeutics is a development stage biopharmaceutical company that develops a fibrin-derived peptide for the treatment of diseases related to vascular leakage. Use the CB Insights …See details»
SIRS Therapeutics and F4 Pharma announce collaboration
Mar 3, 2021 Munich-based SIRS Therapeutics GmbH and Vienna-based F4 Pharma GmbH today announced the signature of a licensing and collaboration agreement with Massachusetts …See details»
Partner Therapeutics Announces Partnership with SIRS …
SIRS Therapeutics GmbH is a development stage biopharmaceutical company that develops FX06, a fibrin-derived peptide for the treatment of diseases related to capillary leakage e.g., …See details»
Systemic Inflammatory Response Syndrome Treatment Market
Jul 8, 2020 According to the World Health Organization, 7/100 hospitalized patients are highly susceptible to infections, which can cause sepsis. The patient-susceptibility rate in developing …See details»
Partner Therapeutics Announces Partnership with SIRS …
Mar 3, 2021 SIRS Therapeutics GmbH is a development stage biopharmaceutical company that develops FX06, a fibrin-derived peptide for the treatment of diseases related to capillary …See details»
SIRS Therapeutics and F4 Pharma announce collaboration with US …
SIRS Therapeutics GmbH is a development stage biopharmaceutical company that develops FX06, a fibrin-derived peptide for the treatment of diseases related to capillary leakage e.g., …See details»
Advanced Systemic Mastocytosis - Everyday Health
1 day ago Advanced systemic mastocytosis, a rare blood disorder, is marked by excessive mast cell growth leading to severe symptoms and potential cancer. ... This national organization …See details»
Systemic Inflammatory Response Syndrome Treatment Market
Advancements in SIRS therapeutics are further brought in due to investment firms established in developed countries, who fund numerous clinical development programs that possess the …See details»
Systemic Therapeutics | Pre-clinical Biotechnology
Systemic Therapeutics Corp. is a Canadian pre-clinical stage, biotechnology company specialized in the development of new therapies focusing on the master regulator of lipid metabolism, …See details»
Systemic Inflammatory Response Syndrome Treatment Market …
Recent Developments in the Systemic Inflammatory Response Syndrome Treatment Market. In April 2024, Enlivex Therapeutics reported positive results for its Phase II clinical trials of …See details»
2024-12-04 | Merus Announces FDA Approval of BIZENGRI
1 day ago BIZENGRI ® is the first and only therapy approved by the FDA specifically for pancreatic adenocarcinoma and NSCLC that harbor NRG1 gene fusions and are advanced …See details»